Tourmaline Bio, Inc. (TRML)
NASDAQ: TRML · Real-Time Price · USD
21.25
+0.91 (4.47%)
Dec 20, 2024, 1:38 PM EST - Market open
Company Description
Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases.
It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders.
The company’s development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED).
The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022.
Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York.
Tourmaline Bio, Inc.
| Country | United States |
| Founded | 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 44 |
| CEO | Sandeep Kulkarni |
Contact Details
Address: 27 West 24th Street, Suite 702 New York, New York 10010 United States | |
| Phone | 646 481 9832 |
| Website | tourmalinebio.com |
Stock Details
| Ticker Symbol | TRML |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001827506 |
| ISIN Number | US89157D1054 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Sandeep C. Kulkarni M.D. | Co-Founder, Chief Executive Officer and Director |
| Dr. Kevin B. Johnson M.B.A., Ph.D. | Chief Regulatory Officer |
| Ryan Robinson CPA | Chief Financial Officer and Treasurer |
| Dr. Susan Dana Jones Ph.D. | Chief Technology Officer |
| W. Bradford Middlekauff J.D. | Chief Business Officer, General Counsel and Corporate Secretary |
| Kimberly Piorkowski | Vice President of People, Culture and Compliance |
| Dora Rau | Senior Vice President and Head of Quality |
| Gerhard Hagn Pharm.D. | Senior Vice President and Head of Commercial and Business Development |
| Dr. Emil M. deGoma M.D. | Senior Vice President of Medical Research |
| Dr. Kristine Erickson O.D., Ph.D. | Vice President and TA Head of Ophthalmology, Medical Research |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 10, 2024 | 8-K | Current Report |
| Dec 10, 2024 | 8-K | Current Report |
| Nov 14, 2024 | EFFECT | Notice of Effectiveness |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | UPLOAD | Filing |
| Nov 8, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |